Cancer and Aging: General Principles, Biology, and Geriatric Assessment.

Clinics in Geriatric Medicine

Volumn 32, Issue 1, 2016, Pages 1-15

  Li, Daneng ^a   de Glas, Nienke A ^b   Hurria, Arti ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Tergooi Hospitals   (Netherlands)

Author keywords

Aging; Biology; Biomarker; Cancer; Geriatric assessment

Indexed keywords

C REACTIVE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; D DIMER; INTERLEUKIN 6; INTERLEUKIN 8; MOLECULAR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGING; BIOACCUMULATION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL AGING; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); GENE MUTATION; GERIATRIC ASSESSMENT; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLOCK; OVERALL SURVIVAL; PLEIOTROPY; REVIEW; STEM CELL; TELOMERE SHORTENING; TOXICITY TESTING; AGE; AGED; ELDERLY CARE; NEOPLASMS; PATIENT CARE; RISK FACTOR; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; GERIATRIC ASSESSMENT; HEALTH SERVICES FOR THE AGED; HUMANS; NEOPLASMS; PATIENT CARE MANAGEMENT; RISK FACTORS;

EID: 84960255232     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2015.08.003     Document Type: Review

References (89)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2012 2015, National Cancer Institute, Bethesda (MD), based on November 2014 SEER data submission, posted to the SEER web site Available at:. http://seer.cancer.gov/csr/1975_2012/.
2. Smith B.D., Smith G.L., Hurria A., et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27:2758-2765.
3. Crome P., Lally F., Cherubini A., et al. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging 2011, 28:667-677.
4. Hansen J. Common cancers in the elderly. Drugs Aging 1998, 13:467-478.
5. Wedding U., Honecker F., Bokemeyer C., et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007, 14:44-56.
6. Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006, 20:135-143.
7. Saltzstein S.L., Behling C.A. 5- and 10-year survival in cancer patients 90 and older. A study of 37,218 patients from SEER. J Surg Oncol 2002, 81:113-116.
8. Extermann M. Management issues for elderly patients with breast cancer. Curr Treat Options Oncol 2004, 5:161-169.
9. Chen H., Cantor A., Meyer J., et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003, 97:1107-1114.
10. Christman K., Muss H.B., Case L.D., et al. Chemotherapy of metastatic breast cancer in the elderly. The Pidemont Oncology Association experience. JAMA 1992, 268:57-62.
11. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.
12. Hubbard J.M., Cohen H.J., Muss H.B. Incorporating biomarkers into cancer and aging research. J Clin Oncol 2014, 32:2611-2616.
13. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001, 285:2750-2756.
14. Lee S.J., Lindquist K., Segal M.R., et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006, 295:801-808.
15. Wildiers H., Heeren P., Puts M. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014, 32:2595-2603.
16. Medawar P.B. Unsolved problems of biology 1952, H.K. Lewis, London.
17. Harman D. Extending functional life span. Exp Gerontol 1998, 33:95-112.
18. Slagboom P.E., Vijg J. The dynamics of genome organization and expression during the aging process. Ann N Y Acad Sci 1992, 673:58-69.
19. Cheng W.H., Muftic D., Muftuoglu M., et al. WRN is required for ATM activation and the S-phase checkpoint in response to interstrand cross-link-induced DNA double-strand breaks. Mol Biol Cell 2008, 19:3923-3933.
20. Williams G.C. Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957, 11:398-411.
21. Holst C.R., Nuovo G.J., Esteller M., et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003, 63:1596-1601.
22. Krishnamurthy J., Torrice C., Ramsey M.R., et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004, 114:1299-1307.
23. Munro J., Barr N.I., Ireland H., et al. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res 2004, 295:525-538.
24. Liu Y., Johnson S.M., Fedoriw Y., et al. Expression of a p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood 2011, 117:3257-3267.
25. Sanoff H.K., Deal A.M., Krishnamurthy J., et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst 2014, 106:dju057.
26. Falandry C., Bonnefoy M., Freyer G., et al. Biology of cancer and aging: a complex association with cellular senescence. J Clin Oncol 2014, 32:2604-2610.
27. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
28. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013, 75:685-705.
29. Coppe J.P., Kauser K., Campisi J., et al. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006, 281:29568-29574.
30. Liu D., Hornsby P.J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007, 67:3117-3126.
31. Laberge R.M., Awad P., Campisi J., et al. Epithelial-mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron 2012, 5:39-44.
32. D'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
33. Gilson E., Geli V. How telomeres are replicated. Nat Rev Mol Cell Biol 2007, 8:825-838.
34. Feldser D.M., Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007, 11:461-469.
35. Cosme-Bianco W., Shen M.F., Lazar A.J., et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007, 8:497-503.
36. Raynaud C.M., Sabatier L., Philipot O., et al. Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit Rev Oncol Hematol 2008, 66:99-117.
37. Ma H., Zhou Z., Wei S., et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One 2011, 6:e20466.
38. Wentzensen I.M., Mirabello L., Pfeiffer R.M., et al. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011, 20:1238-1250.
39. Aschacher T., Wolf B., Enzmann F., et al. LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines. Oncogene 2015, 1-11. [Epub ahead of print].
40. Chin L., Artandi S.E., Shen Q., et al. P53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
41. Greenberg R.A., Chin L., Femino A., et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999, 97:515-525.
42. Vaziri H., Dragowska W., Alllsopp R.C., et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994, 91:9857-9860.
43. Rossi D.J., Seita J., Czechowicz A., et al. Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging. Cell Cycle 2007, 6:2371-2376.
44. Rube C.E., Fricke A., Widmann T.A., et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS One 2011, 6:e17487.
45. TelKippe M., Harrison D.E., Chen J. Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 2003, 31(6):521-527.
46. Berfield A.K., Andress D.L., Abrass C.K. IGFBP-5(201-208) stimulates Cdc42GAP aggregation and filopodia formation in migrating mesangial cells. Kidney Int 2000, 57:1991-2003.
47. Chen J., Ellison F.M., Keyvanfar K., et al. Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol 2008, 36:1236-1243.
48. Matheu A., Maraver A., Klatt P., et al. Delayed aging through damage protection by the Arf/p53 pathway. Nature 2007, 448:375-379.
49. Bondar T., Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010, 6:309-322.
50. Porter C.C., Baturin D., Choudhary R., et al. Relative fitness of hematopoietic progenitors influences leukemia progression. Leukemia 2011, 25:891-895.
51. Xue W., Zender L., Miething C., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
52. Kang T.W., Yevsa T., Woller N., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
53. Blagosklonny M.V. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle 2010, 9:3151-3156.
54. Blagosklonny M.V. Answering the ultimate question "what is the proximal cause of aging?". Aging 2012, 4:861-877.
55. Gems D., Doonan R. Antioxidant defense and aging in C. elegans: is the oxidative damage theory of aging wrong?. Cell Cycle 2009, 8:1681-1687.
56. Gems D., de la Guardia Y. Alternative perspectives on aging in Caenorhabditis elegans: reactive oxygen species or hyperfunction?. Antioxid Redox Signal 2013, 19:321-329.
57. Berman A.E., Leontieva O.V., Natarajan V., et al. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget 2012, 3:1522-1532.
58. Cohen H.J., Harris T., Pieper C.F. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003, 114:180-187.
59. Reuben D.B., Chen Al, Harris T.B., et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 2002, 50:638-644.
60. Pieper C.F., Rao K.M., Currie M.S., et al. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci 2000, 55:M649-M657.
61. Flandry C., Gilson E., Rudolph K.L. Are aging biomarkers clinically relevant in oncogeriatrics?. Crit Rev Oncol Hematol 2013, 85:257-265.
62. Liu Y., Sanoff H.K., Cho H., et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009, 8:439-448.
63. Song Z., von Figura G., Liu Y., et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 2010, 9:607-615.
64. Pallis A.G., Hatse S., Brouwers B., et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?. J Geriatr Oncol 2014, 5:204-218.
65. Muss H.B., Krishnamurthy J., Alston S.M., et al. P16INK4a expression after chemotherapy in older women with early-stage breast cancer. J Clin Oncol 2011, 29:550s. (suppl; abstract: 9002).
66. Cawthon R.M., Smith K.R., O'Brien E., et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003, 361:393-395.
67. Risques R.A., Arbeev K.G., Yashin A.L., et al. Leukocyte telomere length is associated with disability in older US population. J Am Geriatr Soc 2010, 58:1289-1298.
68. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during aging of human fibroblasts. Nature 1990, 345:458-460.
69. Mather K.A., Jorm A.F., Parslow R.A., et al. Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci 2011, 66:202-213.
70. Jiang H., Schiffer E., Song Z., et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 2008, 105:11299-11304.
71. National Comprehensive Cancer Network (NCCN). Older Adult Oncology (Version 2.2015). Available at: . Accessed June 20, 2015. http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf.
72. Puts M., Hardt J., Monette J., et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 2012, 104:1133-1163.
73. Hamaker M.E., Schiphorst A.H., ten Bokkel Huinink D., et al. The effect of a geriatric evaluation on treatment decisions for older cancer patients-a systematic review. Acta Oncol 2014, 53:289-296.
74. Kenis C., Bron D., Libert Y., et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 2013, 24:1306-1312.
75. Extermann M., Boler I., Reich R., et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012, 118:3377-3386.
76. Hurria A., Togawa K., Mohile S., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29:2457-2465.
77. Kenig J., Olszewska U., Zychiewicz B., et al. Cumulative deficit model of geriatric assessment to predict the postoperative outcomes of older patient with solid abdominal cancer. J Geriatr Oncol 2015, [Epub ahead of print].
78. Hamaker M.E., Vos A.G., Smorenburg C.H., et al. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 2012, 17:1439-1449.
79. Kanesvaran R., Li H., Koo K.N., et al. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol 2011, 29:3620-3627.
80. Klepin H.D., Geiger A.M., Tooze J.A., et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013, 121:4287-4294.
81. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19:980-991.
82. de Glas N.A., van de Water W., Engelhardt E.G., et al. Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. Lancet Oncol 2014, 15:722-729.
83. Repetto L., Fratino L. Geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 2002, 20:494-502.
84. Caillet P., Canoui-Poitrine F., Vouriot J., et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011, 29:3636-3642.
85. Pallis A.G., Ring A., Fortpied C., et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 2011, 22:1922-1926.
86. Wildiers H., Mauer M., Pallis A., et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology position article. J Clin Oncol 2013, 31:3711-3718.
87. Hurria A., Dale W., Mooney M., et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 2014, 32:2587-2594.
88. van de Water W., Kiderlen M., Bastiaannet E., et al. External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer. J Natl Cancer Inst 2014, 106:dju051.
89. Kalsi T., Babic-Illman G., Ross P.J., et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer 2015, 112:1435-1444.